Please assess the completion status of the following clinical trial:

Trial Title: Add-on Effects of Valsartan on Morbi- Mortality (KYOTO HEART Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of hypertension~* Clinical diagnosis of one or more risk factors, such as diabetes, smoking habit, lipid metabolism abnormality, history of ischemic heart disease (IHD) or cerebrovascular disease, obesity (BMI\>25), chronic heart failure (NYHA II-III), and electrocardiogram (ECG) abnormality (LVH)~Exclusion Criteria:~* Patients who have already been administered ARB~* Patients with IHD within 6 months after percutaneous coronary intervention(PCI), and who are stable but are going to implement PCI or coronary artery bypass grafting(CABG)~* Severe/malignant/secondary hypertensive patients~* Pregnant women and women of childbearing potential~* History of heart failure, unstable angina, myocardial infarction, PTCA, or CABG within the preceding 6 months~* Arrhythmia needed to be treated or accompanied with symptoms, second or third degree AV block~* Severe renal impairment (Serum creatinine \>3.0 mg/dl)~* Severe hepatic impairment (Hepatic failure, Cirrhosis, etc.)

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Non-ARB (Type: ACTIVE_COMPARATOR): 'Non-ARB' was defined as Conventional anti-hypertensive treatment except for ARB and ACEIs
- Valsartan (Type: EXPERIMENTAL): Valsartan add-on treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).